

**Table S1** Tumor response in cohorts A and B

Parameters	Anlotinib + erlotinib (cohort A) (n=30)	Anlotinib + pemetrexed/gemcitabine + carboplatin (cohort B) (n=30)
BOR, n (%)		
CR	0	0
PR	26 (86.7)	18 (60.0)
SD	1 (3.3)	11 (36.7)
PD	0	1 (3.3)
NE	3 (10.0)	0
ORR, n (%) (95% CI)	26 (86.7) (69.3–96.2)	18 (60.0) (40.6–77.3)
DCR, n (%) (95% CI)	27 (90.0) (73.5–97.9)	29 (96.7) (82.8–99.9)

BOR, best overall response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; DCR, disease control rate; CI, confidence interval.

**Table S2** Intracranial tumor response of patients with brain metastasis in cohort A

Parameters	Anlotinib + erlotinib (cohort A) (n=9)
CR, n (%)	3 (33.3)
PR, n (%)	2 (22.2)
SD, n (%)	1 (11.1)
NE, n (%)	2 (22.2)
PD, n (%)	1 (11.1)
iORR, n (%)	5 (55.6)
iDCR, n (%)	8 (88.9)

CR, complete response; PR, partial response; SD, stable disease; NE, not evaluable; PD, progressive disease; iORR, intracranial objective response rate; iDCR, intracranial disease control rate.